Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756378 | 1.00 | PPARG (0.38) | PPARGMAOBNR4A2PARP10MAOA | |
| SCHEMBL752092 | 0.83 | CNR2 (0.35) | — | |
| SCHEMBL752091 | 0.83 | CNR2 (0.35) | — | |
| SCHEMBL753724 | 0.79 | GRM2 (0.34) | — | |
| SCHEMBL753725 | 0.79 | GRM2 (0.34) | — | |
| SCHEMBL16921583 | 0.77 | NR4A2 (0.48) | MAOBNR4A2PARP10MAOAFFAR1 | |
| SCHEMBL754321 | 0.77 | NR4A2 (0.48) | MAOBNR4A2PARP10MAOAFFAR1 | |
| SCHEMBL755968 | 0.67 | MAOB (0.56) | MAOBNR4A2PARP10MAOAALKBH1 | |
| SCHEMBL1563358 | 0.65 | MAOB (0.51) | PPARGMAOBFFAR1 | |
| SCHEMBL13754898 | 0.65 | MAOB (0.51) | PPARGMAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | PPARG 4065/4885MAOB 709/4885NR4A2 907/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | PPARG 3165/4885MAOB 900/4885NR4A2 949/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | PPARG 3165/4885MAOB 900/4885NR4A2 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.